류마티스관절염 환자의 심혈관 질환 및 당뇨병 위험분석: a propensity score analysis = The Risk of Cardiovascular Disease and Diabetes in Rheumatoid Arthritis Patients: A Propensity Score Analysis

다국어 초록 (Multilingual Abstract)

Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests as joint damage or athletic disability via sustained inflammation of the synovial membrane. The risk of cardiovascular disease (CVD) is higher in RA patients. This study aimed at evaluating the association between CVD comorbidities and RA by comparing a pharmacotherapy group with a nonpharmacotherapy group. Methods: Patient sample data from the Health Insurance Review and Assessment Service (HIRA-NPS- 2016) were used. Inverse probability of treatment weighting (IPTW) using the propensity score was used to minimize the differences in patient characteristics. Logistic regression analysis was used to evaluate the risk of CVD comorbidities. Results: The analyses included 1,207,213 patients, of which 33,122 (2.8%) had RA. The odds ratios (OR) of CVD comorbidities were increased in RA patients; ischemic heart disease (IHD: OR 1.75; 95% CI 1.73, 1.77), cerebral infarction (CERI: OR 1.28; 95% CI 1.26, 1.30), hypertension (HTN: OR 1.44; 95% CI 1.43, 1.45), diabetes mellitus (DM: OR 2.04; 95% CI 2.03, 2.06), and dyslipidemia (DL: OR 3.49; 95% CI 3.47, 3.51). The ORs of IHD, CERI, HTN, and DM in the traditional DMARD and biologic treatment groups were decreased, compared with those in the non-pharmacotherapy group. Conclusions: Thus, CVD risk was higher in RA patients, considering age, sex, and socioeconomic status. Appropriate pharmacotherapy could decrease the risk of CVD comorbidities in RA patients.

참고문헌 (Reference)

1 Greenberg JD, "Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis" 70 : 576-582, 2011

2 Minichiello E, "Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review" 83 (83): 625-630, 2016

3 van Sijl AM, "The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a metaanalysis" 41 : 393-400, 2011

4 Barnabe C, "Systematic review and metaanalysis:anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis" 63 : 522-529, 2011

5 Micha R, "Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease" 108 (108): 1362-1370, 2011

6 Aviña-Zubieta JA, "Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies" 59 : 1690-1697, 2008

7 Scott DL, "Rheumatoid arthritis" 376 : 1094-1108, 2010

8 Ljung L, "Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis" 75 : 2087-2094, 2016

9 Hunter TM, "Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014" 37 (37): 1551-1557, 2017

10 Austin PC, "Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies" 34 (34): 3661-3679, 2015

11 Merkle CJ, "Methotrexate causes apoptosis in postmitotic endothelial cells" 2 : 5-14, 2000

12 Choi HK, "Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study" 359 : 1173-1177, 2002

13 Rempenault C, "Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis" 77 (77): 98-103, 2018

14 Elke EA Arts, "Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study" BMJ 76 (76): 1693-1699, 2017

15 Boo S, "Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis" 12 : e0176291-, 2017

16 Glynn RJ, "Indications for propensity scores and review of their use in pharmacoepidemiology" 98 (98): 253-259, 2006

17 Bryant R England, "Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications" BMJ 23 (23): k1036-, 2018

18 Naqvi AA, "Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients: A systematic review and meta-analysis" 69 : 389-398, 2019

19 Silman AJ, "Epidemiology and genetics of rheumatoid arthritis" 4 (4): S265-S272, 2002

20 Dierkes J, "Effect of drugs on homocysteine concentrations" 5 : 124-139, 2005

21 Agca R, "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders:2015/2016 update" 76 : 17-28, 2017

22 Solomon DH, "Disease activity in rheumatoid arthritis and the risk of cardiovascular events" 67 : 1449-1455, 2015

23 Nicola PJ, "Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis" 54 : 60-67, 2006

24 Sandoo A, "Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study" 15 : R203-, 2013

25 Robertson J, "Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm" 9 : 513-523, 2013

26 Lim DT, "Cardiovascular risk and the use of biologic agents in rheumatoid arthritis" 16 : 459-, 2014

27 Liao KP, "Cardiovascular disease in patients with rheumatoid arthritis" 27 : 136-140, 2017

28 Schmidt TJ, "Cardiovascular Disease Prevention in Rheumatoid Arthritis: Compliance with Diabetes Screening Guidelines" 45 : 1367-1374, 2018

29 O'Neill F, "Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis" 103 : 766-773, 2017

30 Saag KG, "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis" 59 : 762-784, 2008

31 Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples" 36 : e2014008-, 2014

32 Singh JA, "2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis" 68 (68): 1-25, 2016

33 Singh JA, "2012 Update of the 2008American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis" 64 : 625-639, 2012